Efficacy and safety of pegylated interferon plus ribavirin for the treatment of hepatitis C virus-positive cryoglobulinemic glomerulonephritis

Cesare Mazzaro, Giacomo Panarello, Endri Mauro, Valter Gattei, Gabriele Pozzato

Research output: Contribution to journalArticle

Abstract

Background: The most frequent form of renal involvement in patients with hepatitis C infection is cryoglobulinemic membrano-proliferative glomerulonephritis. Nonetheless, some reports indicate that the eradication of the hepatitis C virus may also lead to the remission of this renal disease. Methods: The virological, immunological and nephrological response to pegylated interferon α plus ribavirin (48 weeks in patients infected with genotype 1, and 24 weeks for patients infected with genotypes 2 and 3) was evaluated retrospectively in 10 patients with cryoglobulinemic glomerulonephritis. Results: 6 patients obtained end of treatment virological response (60%); during follow-up, 2 relapsed, and 4 patients maintained a sustained virological response (40%). At the end of follow-up, three patients obtained a significant nephrological response and decrease in cryoglobulin levels (p<0.05). No significant changes in clinical and biological parameters were observed in non-responders/relapsers. Conclusions: Eradication of hepatitis C may be associated with the regression of cryoglobulinemic glomerulonephritis.

Original languageEnglish
Pages (from-to)613-616
Number of pages4
JournalDigestive and Liver Disease
Volume47
Issue number7
DOIs
Publication statusPublished - Jul 1 2015

Keywords

  • HCV-genotype
  • Hepatitis C virus
  • Membrano-proliferative glomerulo-nephritis

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Fingerprint Dive into the research topics of 'Efficacy and safety of pegylated interferon plus ribavirin for the treatment of hepatitis C virus-positive cryoglobulinemic glomerulonephritis'. Together they form a unique fingerprint.

  • Cite this